AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Envelaf 150mg Capsule XR

Prescription Icon
Prescription Required

Marketer

Alkem Laboratories Ltd

Salt Composition

Venlafaxine (150mg)

Overview Envelaf 150mg Capsule XR

Axilon 150mg Extended-Release Capsules treat depression and anxiety. It modifies brain chemistry responsible for anxiety symptoms like agitation, edginess, poor concentration, tiredness, perspiration, rapid heartbeat, and racing thoughts. Take Axilon 150mg Extended-Release Capsules with food, at the same time daily for consistent blood levels. If a dose is missed, take it immediately upon recall. Complete the prescribed course, even if feeling improved; abruptly stopping may worsen symptoms. Common side effects include queasiness, vomiting, sleeplessness, reduced appetite, anxiety, bowel irregularity, increased sweating, and sexual difficulties. Dizziness and drowsiness may occur; avoid driving or mentally demanding tasks until the medication's effects are known. These side effects are typically temporary and self-limiting. Report persistent or bothersome side effects to your physician. Before starting Axilon 150mg Extended-Release Capsules, disclose kidney, heart, or liver issues, or a history of seizures. Report any unusual mood or behavioral changes, worsening depression, or suicidal thoughts to your doctor immediately.

Uses of Envelaf 150mg Capsule XR

Mood disorders encompassing depressive and anxious symptoms

Major Benefits of Envelaf 150mg Capsule XR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the entire capsule; avoid chewing, crushing, or fracturing it. The Envelaf 150mg extended-release capsule should be administered with a meal.

Common Side effects of Envelaf 150mg Capsule XR:

  • Nausea
  • Vomiting
  • Dizziness
  • Insomnia (difficulty in sleeping)
  • Decreased appetite
  • Anxiety
  • Constipation
  • Increased sweating
  • Sexual dysfunction

How to use Envelaf 150mg Capsule XR:

Follow your doctor's instructions precisely regarding dosage and treatment length for Envelaf 150mg XR Capsules. Ingest the capsules whole; avoid crushing, chewing, or breaking them. Administer this medication with a meal.

How Envelaf 150mg Capsule XR works:

Envelaf 150mg Extended-Release Capsules elevate brain levels of serotonin and noradrenaline, neurotransmitters crucial for emotional equilibrium.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Envelaf 150mg Capsule XR and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Envelaf 150mg capsules may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the treatment's advantages against possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Envelaf 150mg capsules are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant. Close observation of infants for drowsiness and appropriate weight increase is recommended.

DrivingDrivingUNSAFE

Driving ability may be impaired by Envelaf 150mg XR capsules, due to potential side effects including dizziness, confusion, and visual disturbances like blurred vision.

KidneyKidneyCAUTION

Extended-release Envelaf 150mg capsules require careful administration for individuals with impaired kidney function. Dosage modification of Envelaf 150mg XR capsules might be necessary. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should use Envelaf 150mg extended-release capsules cautiously; dosage modification may be necessary. Physician consultation is advised.

What if you forget to take Envelaf 150mg Capsule XR :

For a missed Envelaf 150mg Capsule XR dose, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Envelaf 150mg Capsule XR

LabelValue
Type of Compound Methoxybenzene compound
Addictive None.
Type of Medication Nervous System
Mechanism of Action Drugs that block the reabsorption of serotonin and norepinephrine.

FAQs on Envelaf 150mg Capsule XR

Affirmative. Envelaf 150mg extended-release capsules may induce drowsiness. Prior to commencing Envelaf 150mg extended-release capsules, disclose any concurrent use of sleep medications to your physician.
Affirmative. Envelaf 150mg extended-release capsules are classified as a psychotropic medication. Psychotropic medications are defined as those impacting mental processes, feelings, and actions.
Envelaf 150mg extended-release capsules are not classified as narcotics. Narcotics are opioid-derived substances, such as heroin and morphine, known for their sedative effects.
These are equivalent medications. Envelaf 150mg capsules, designated XR or ER, are extended-release formulations, delivering the drug gradually for sustained therapeutic levels. Extended-release tablets reduce the required dosing frequency.
Mirtazapine and Envelaf 150mg XR capsules should not be taken together. Concurrent use carries a significant risk of serotonin syndrome, a potentially fatal condition. Symptoms may include agitation, hallucinations, nausea, vomiting, diarrhea, rapid heart rate, fluctuating blood pressure, fever, and coma.
Concurrent use of citalopram and envelaf 150mg extended-release capsules elevates serotonin levels, posing a risk of serotonin syndrome. An alternative medication is advised to prevent this potentially fatal condition, which may manifest as restlessness, visual or auditory disturbances, nausea, vomiting, diarrhea, rapid heart rate, fluctuating blood pressure, fever, and unconsciousness.
Envelaf 150mg Capsule XR is actively removed from the brain by p-glycoprotein. Research indicates that both Envelaf 150mg Capsule XR and its byproduct suppress p-glycoprotein activity.
Extended-release Envelaf 150mg capsules are absorbed into the body via the intestinal tract following hepatic metabolism.
Extended-release Envelaf 150mg capsules are prescribed for the management of major depressive disorder. Physician consultation is required prior to use.
Treatment with Envelaf 150mg extended-release capsules has been linked to persistent elevation of blood pressure in certain individuals. Regular blood pressure checks are advised for patients using Envelaf 150mg extended-release capsules. In these cases, a dosage decrease or treatment cessation may be necessary.
Indeed, Envelaf 150mg extended-release capsules can induce constipation in certain individuals. A high-fiber diet and increased water intake are recommended. Laxative use may also be considered. Your physician can advise on preventative measures and management strategies. If constipation persists or worsens, seek medical attention.
Indeed, some individuals taking Envelaf 150mg Extended-Release Capsules experience weight reduction. Clinical trials revealed a correlation between dosage and weight loss in patients using Envelaf 150mg Extended-Release Capsules for extended periods. If this side effect concerns you, seek medical advice.
Envelaf 150mg extended-release capsules are not considered habit-forming.
Capsules may be substituted with tablets only if a physician authorizes the change. Self-initiated alterations are inadvisable, as varying drug formulations affect release profiles and, consequently, therapeutic efficacy. Such changes risk inadequate treatment, potential adverse reactions, and treatment failure.
Concurrent use of gabapentin and Envelaf 150mg extended-release capsules requires medical supervision. Combined administration may heighten drowsiness, somnolence, and impair concentration. Proceed with caution.
Desvenlafaxine, a pharmacologically active product of Envelaf 150mg Capsule XR, represents the drug's biologically active component.
Extended-release Envelaf 150mg capsules lack regulatory approval for fibromyalgia treatment. Preliminary research suggests potential efficacy, but further investigation is needed. Physician consultation is essential prior to commencing this medication.
Extended-release Envelaf 150mg capsules lack formal approval for treating neuropathic pain, although studies suggest its effectiveness in this area. Consequently, its use for nerve pain is currently considered off-label.
Extended-release Envelaf 150mg capsules are associated with alterations in brain neurochemistry, resulting in reduced appetite. This appetite suppression is correlated with the administered dose.
Should you experience reduced libido or erectile dysfunction, consult your physician to discuss alternative treatment options. Do not discontinue Envelaf 150mg Capsule XR independently; this may worsen side effects.
Envelaf 150mg Capsule XR
43
MRP 52
17% off